Clinical trial endpoints for metabolic dysfunction and alcohol associated steatotic liver disease

Hepatology International · Published 2026-05-19 · DOI 10.1007/s12072-026-11096-2

Authors (4)

Chencheng Xie, Mohamed A. Elfeki, Winston Dunn, Ashwani K. Singal

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Xie, C., Elfeki, M., Dunn, W., et al. (2026). Clinical trial endpoints for metabolic dysfunction and alcohol associated steatotic liver disease. Hepatology International. https://doi.org/10.1007/s12072-026-11096-2

Related articles

• APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update · Hepatology International · 2026 · Same journal
• APASL STC on Wilson Disease; New Delhi 2026 · Hepatology International · 2026 · Same journal
• Tolvaptan for hyponatremia in patients with cirrhosis: a post hoc subgroup analysis of a multicenter, randomized, double-blind, placebo-controlled trial · Hepatology International · 2026 · Same journal
• Phosphatidylethanol versus clinical criteria to diagnose alcohol use relapse after liver transplantation: a prospective cohort study · Hepatology International · 2026 · Same journal
• Precision medicine for G-CSF in ACLF: the biomarker gap · Hepatology International · 2026 · Same journal
• Response to letter to editor—Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon · Hepatology International · 2026 · Same journal
• Methodological Considerations in the MAFLD-MASLD Dichotomy for Cardiac Risk Assessment · Hepatology International · 2026 · Same journal
• Obstructive sleep apnea mediates the association between body mass index and metabolic dysfunction-associated steatotic liver disease in patients with obesity · Hepatology International · 2026 · Same journal
• Gout is independently associated with occult hepatic fibro-inflammation independent of obesity: a multi-cohort study using MRI-cT1 and elastography · Hepatology International · 2026 · Same journal
• FXR overexpression promotes liver regeneration through inducing FGF2 activation in APAP-induced acute liver injury · Hepatology International · 2026 · Same journal